Advaxis to Provide 2013 Business Outlook on March 6, 2013
Advaxis to Provide 2013 Business Outlook on March 6, 2013
-Management to discuss progress with and plans for advancing its lead development program and outline expected clinical milestones for the year-
-Management committed to further strengthening financial position and execution on strategic priorities-
-Conference call and webcast at 5 p.m. ET-
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases today announces a conference call and live audio webcast to be held on Wednesday, March 6, 2013 at 5 p.m. ET to discuss the Company's 2013 business outlook, including progress with and plans for advancing its lead development program, expected clinical and corporate milestones for the year and its momentum and continued plans for further strengthening its financial position.
Advaxis will also provide an update on the timing of the data release from the second of three dose cohorts in Lm-LLO-E7-07, a randomized, single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3. The Company previously announced that it expected to report this data earlier in the first quarter of 2013. However, data are still being collected and analyzed from some of the clinical trial sites, therefore the results from Cohort 2 have not yet been made available to the Company's management team. The Company now expects to announce this data early in the second quarter of 2013.
The conference call and live audio webcast on March 6, 2013 will be hosted by Thomas A. Moore, Chairman and Chief Executive Officer. He will be joined on the call by members of the Advaxis management team. Interested participants and investors may access the conference call at 5:00 p.m. ET by dialing 800-688-0836 (U.S./Canada) or 617-614-4072 (international); participant code 70014771.
A live audio webcast can also be accessed via the News section, Events and Presentations Tab of the Advaxis corporate web site at http://www.advaxis.com/news/events-presentations, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.
The slide presentation for the conference call/webcast will also be available at http://www.advaxis.com/news/events-presentations.
A telephonic replay of the call will be available for seven days beginning at 8:00 p.m. ET on March 6, 2013. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 55408167.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.
In April 2012, Advaxis' lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website.
Advaxis' lead construct, ADXS-HPV, is being evaluated in 5 ongoing clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), head & neckcancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trial.gov Identifier NCT01671488). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, Brown University Oncology Group, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at www.sec.gov . The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
KEYWORDS: United States North America New Jersey
The article Advaxis to Provide 2013 Business Outlook on March 6, 2013 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.